DelveInsight Publishes Report on Complement C3 Inhibitors Pipeline
Market research firm DelveInsight has released a new report detailing the pipeline of drugs targeting Complement C3 inhibitors. The report covers insights into over 6 companies and 8 pipeline drugs.
DelveInsight, a provider of business intelligence, has published a report analyzing the development status and pipeline of Complement C3 inhibitors. The report identifies more than six companies and eight drug candidates globally, spanning various stages of development. It offers a comprehensive overview of the research and development activities in this therapeutic area.
The report delves into the role of Complement C3, a protein crucial for the innate immune system and a central component of the complement cascade. Its involvement in immune responses makes it a significant target for therapeutic interventions in several diseases.
The analysis covers multiple investigational drugs across different development phases, including clinical trials and preclinical research. The report details each drug candidate's mechanism of action, clinical study progress, and any associated collaborations or agreements.
Notable examples highlighted in the report include Apellis Pharmaceuticals' pegcetacoplan, currently being evaluated for conditions such as paroxysmal nocturnal hemoglobinuria (PNH) and geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The report also mentions Amyndas Pharmaceuticals' AMY-101, another C3-targeted therapeutic candidate.